Aesculap Biologics Announces NOVOCART 3D Trial Enrollment Milestone

Aesculap Biologics achieved 50% enrollment in an ongoing Phase III clinical trial of NOVOCART® 3D, an autologous chondrocyte transplantation system designed to treat knee articular cartilage defects. Approximately 117 study participants have been treated.

The prospective, randomized, partially blinded study, which began in 2014, will enroll a...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us